Literature DB >> 12070055

Inhaled glucocorticosteroids and chronic obstructive pulmonary disease: how full is the glass?

Romain Pauwels.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12070055     DOI： 10.1164/rccm.2204029

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  5 in total

Review 1.  Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes.

Authors:  Gerald Gartlehner; Richard A Hansen; Shannon S Carson; Kathleen N Lohr
Journal:  Ann Fam Med       Date:  2006 May-Jun       Impact factor: 5.166

Review 2.  [Pulmonary diseases in the elderly. Problems of pharmacotherapy].

Authors:  D Ukena
Journal:  Internist (Berl)       Date:  2003-08       Impact factor: 0.743

Review 3.  Nitric oxide, nitrotyrosine, and nitric oxide modulators in asthma and chronic obstructive pulmonary disease.

Authors:  Sergei A Kharitonov; Peter J Barnes
Journal:  Curr Allergy Asthma Rep       Date:  2003-03       Impact factor: 4.919

4.  Outcomes in COPD patients receiving tiotropium or salmeterol plus treatment with inhaled corticosteroids.

Authors:  Richard Hodder; Steven Kesten; Shailendra Menjoge; Klaus Viel
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

Review 5.  Treating COPD with PDE 4 inhibitors.

Authors:  William M Brown
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.